Zevra Therapeutics Q2 EPS $(0.15) Beats $(0.39) Estimate, Sales $8.47M Beat $2.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics reported Q2 earnings per share (EPS) of $(0.15), beating the analyst consensus estimate of $(0.39) by 61.54%. This is a 78.57% increase over losses from the same period last year. The company also reported quarterly sales of $8.47 million, beating the analyst consensus estimate of $2.90 million by 192.07%. This is a 551.54% increase over sales from the same period last year.
August 14, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zevra Therapeutics reported better than expected Q2 earnings and sales, which could positively impact the stock price.
Zevra Therapeutics reported Q2 earnings and sales that significantly beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100